Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing

• Published in: Frontiers in oncology Vol. 12; p. 859846
• Main Authors: Varughese, Lisa A, Bhupathiraju, Madhuri, Hoffecker, Glenda, Terek, Shannon, Harr, Margaret, Hakonarson, Hakon, Cambareri, Christine, Marini, Jessica, Landgraf, Jeffrey, Chen, Jinbo, Kanter, Genevieve, Lau-Min, Kelsey S, Massa, Ryan C, Damjanov, Nevena, Reddy, Nandi J, Oyer, Randall A, Teitelbaum, Ursina R, Tuteja, Sony
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 05.07.2022
• Subjects: cancer; chemotherapy; DPYD; Oncology; pharmacogenetics; toxicity; UGT1A1; toxicity; UGT1A1; pragmatic trial; DPYD; cancer; chemotherapy; pharmacogenetics; implementation science
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2022.859846

Fluoropyrimidines (fluorouracil [5-FU], capecitabine) and irinotecan are commonly prescribed chemotherapy agents for gastrointestinal (GI) malignancies. Pharmacogenetic (PGx) testing for germline and variants associated with reduced enzyme activity holds the potential to identify patients at high risk for severe chemotherapy-induced toxicity. Slow adoption of PGx testing in routine clinical care is due to implementation barriers, including long test turnaround times, lack of integration in the electronic health record (EHR), and ambiguity in test cost coverage. We sought to establish PGx testing in our health system following the Exploration, Preparation, Implementation, Sustainment (EPIS) framework as a guide. Our implementation study aims to address barriers to PGx testing. The Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI) study is a non-randomized, pragmatic, open-label implementation study at three sites within a major academic health system. Eligible patients with a GI malignancy indicated for treatment with 5-FU, capecitabine, or irinotecan will undergo PGx testing prior to chemotherapy initiation. Specimens will be sent to an academic clinical laboratory followed by return of results in the EHR with appropriate clinical decision support for the care team. We hypothesize that the availability of a rapid turnaround PGx test with specific dosing recommendations will increase PGx test utilization to guide pharmacotherapy decisions and improve patient safety outcomes. Primary implementation endpoints are feasibility, fidelity, and penetrance. Exploratory analyses for clinical effectiveness of genotyping will include assessing grade ≥3 treatment-related toxicity using available clinical data, patient-reported outcomes, and quality of life measures. We describe the formative work conducted to prepare our health system for and testing. Our prospective implementation study will evaluate the clinical implementation of this testing program and create the infrastructure necessary to ensure sustainability of PGx testing in our health system. The results of this study may help other institutions interested in implementing PGx testing in oncology care. https://clinicaltrials.gov/ct2/show/NCT04736472, identifier [NCT04736472].